Published in J Biomed Res on January 19, 2017
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Cancer genome landscapes. Science (2013) 25.33
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Wnt/β-catenin signaling and disease. Cell (2012) 16.05
Colorectal cancer statistics, 2014. CA Cancer J Clin (2014) 12.86
The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A (1999) 10.75
Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta (2003) 7.85
The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev (1996) 7.78
Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A (1995) 7.31
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev (2006) 6.75
The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev (1999) 6.56
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell (2004) 4.98
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res (2000) 2.00
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res (1997) 1.96
Cyclic nucleotide-dependent protein kinases. Pharmacol Ther (1991) 1.94
ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell (2002) 1.86
cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res (2007) 1.80
The biology of cyclic GMP-dependent protein kinases. J Biol Chem (2004) 1.75
Wnt proteins. Cold Spring Harb Perspect Biol (2012) 1.70
Studies of neoplasia in the Min mouse. Biochim Biophys Acta (1997) 1.63
Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis (1996) 1.62
Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol (2001) 1.61
Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol (2002) 1.57
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
Homozygosity for the Min allele of Apc results in disruption of mouse development prior to gastrulation. Dev Dyn (1995) 1.50
Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest (2000) 1.44
cAMP-dependent vasodilators cross-activate the cGMP-dependent protein kinase to stimulate BK(Ca) channel activity in coronary artery smooth muscle cells. Circ Res (2000) 1.34
Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther (2009) 1.31
Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol (2008) 1.26
Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol (2014) 1.26
Altered expression and mutation of beta-catenin gene in gastric carcinomas and cell lines. Int J Cancer (2001) 1.24
Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res (2004) 1.19
Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila) (2011) 1.13
Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol Cancer Ther (2002) 1.12
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity. Cancer Prev Res (Phila) (2012) 1.11
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer Ther (2013) 1.10
Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog (2008) 1.08
Generation of a unique strain of multiple intestinal neoplasia (Apc(+/Min-FCCC)) mice with significantly increased numbers of colorectal adenomas. Mol Carcinog (2005) 1.07
Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2008) 1.07
PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4. Oncogene (2010) 1.06
Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Clin Exp Metastasis (2012) 1.02
Sulindac metabolism: the importance of an intact colon. Clin Pharmacol Ther (1985) 0.97
Functional consequences of Wnt-induced dishevelled 2 phosphorylation in canonical and noncanonical Wnt signaling. J Biol Chem (2013) 0.94
FOXO1 inhibits osteosarcoma oncogenesis via Wnt/β-catenin pathway suppression. Oncogenesis (2015) 0.91
Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients. Mol Cancer (2008) 0.90
Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468. Cell Prolif (2012) 0.86
The uroguanylin system and human disease. Clin Sci (Lond) (2012) 0.82
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity. Oncogene (2014) 0.81
cGMP-Dependent Protein Kinase Inhibitors in Health and Disease. Pharmaceuticals (Basel) (2013) 0.79
Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. Oncotarget (2015) 0.78
β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG. Oncotarget (2016) 0.77
PDE2 is a novel target for attenuating tumor formation in a mouse model of UVB-induced skin carcinogenesis. PLoS One (2014) 0.75
The interaction between the Wnt/β-catenin signaling cascade and PKG activation in cancer. J Biomed Res (2017) 0.75